Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (DE:8QQ)
FRANKFURT:8QQ
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful progress in AbCellera's strategic transition to a clinical-stage biotech: solid liquidity (~$700M available), completion of platform and manufacturing investments, successful nomination and clinic advancement of multiple internal candidates, and a roadmap of near- and mid-term clinical catalysts (notably ABCL635 Phase II readout in Q3 2026). At the same time, notable risks and near-term challenges were acknowledged: revenue growth in 2025 was materially influenced by a one-time legal settlement, research fee revenues are expected to decline as the company pivots to internal programs, R&D spending and cash burn remain elevated, and lead programs face clinical and class-specific safety uncertainties that could delay value realization. Overall, the positive operational and pipeline milestones and strong liquidity outweigh the near-term financial and clinical risks.Company Guidance
Strong Liquidity Position
Approximately $561 million in cash, cash equivalents and marketable securities at quarter end, with an additional ~$140 million in committed government funding, yielding roughly $700 million in total available liquidity to execute the strategy.
Transition to Clinical-Stage Biotech and Pipeline Expansion
Successfully delivered on four corporate priorities for 2025 and exceeded one by nominating two development candidates. ABCL635 advanced into a randomized, double-blind, placebo-controlled Phase II study; ABCL575 is in Phase I; ABCL688 and ABCL386 are in IND‑enabling activities. More than 20 programs in discovery and an expectation to advance a fifth program into IND-enabling activities in H1 2026.
Near- and Mid-Term Clinical Catalysts
Management expects 2 clinical readouts in 2026 (including ABCL635 Phase II readout anticipated in Q3 2026) and plans for multiple catalysts in 2027 with an anticipated five clinical-stage programs by mid-2027.
Revenue Increase Year-over-Year
Total revenue for 2025 was $75 million versus ~$29 million in 2024, an increase of approximately 158.6%, driven largely by $36 million from a patent settlement with Bruker and $47 million in licensing and royalty payments (and $27 million from partnered program work).
Improved Net Loss and EPS Trend
Net loss improved to approximately $146 million in 2025 from about $163 million in 2024, representing a reduction in loss of ~10.4%. Reported loss per share was $0.49 (basic and diluted).
Increased R&D Investment to Support Internal Pipeline
Research and development expenses rose to $187 million in 2025, about $20 million higher than the prior year (~+12%), reflecting deliberate investment in advancing proprietary programs and internal capabilities.
Clinical Manufacturing and Capital Investments
Substantial completion of clinical manufacturing facility and continued PP&E investments to establish clinical manufacturing capabilities, intended to improve supply chain control, flexibility and IP protection; real estate and other financing actions provided $63 million in liquidity during the quarter.
Discovery-to-Clinic Track Record
Cumulative total of 104 partner-initiated programs with downstream participation; 19 molecules discovered by or via licensed technology have reached the clinic. Of the 104 programs, management reported roughly 48 programs currently actively progressing (~46%).
DE:8QQ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:8QQ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | €2.73 | €2.71 | -0.77% |
Nov 06, 2025 | €4.20 | €3.30 | -21.43% |
Aug 07, 2025 | €3.50 | €3.53 | +0.94% |
May 08, 2025 | €1.77 | €1.84 | +4.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AbCellera Biologics (DE:8QQ) report earnings?
AbCellera Biologics (DE:8QQ) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is AbCellera Biologics (DE:8QQ) earnings time?
AbCellera Biologics (DE:8QQ) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of AbCellera Biologics stock?
The P/E ratio of AbCellera Biologics is N/A.
What is DE:8QQ EPS forecast?
DE:8QQ EPS forecast for the fiscal quarter 2026 (Q1) is -0.13.